Prospect: information for the user
Boostrix Polio, Pre-filled syringe suspension
Diphtheria, tetanus, pertussis (acellular component) and inactivated poliomyelitis (adsorbed, reduced antigen content) vaccine
Read this prospect carefully before you or your child receives this vaccine, as it contains important information for you.
Boostrix Polio is a vaccine indicated for booster vaccination in children from 3 years old, adolescents, and adults to prevent four diseases: diphtheria, tetanus (lockjaw), pertussis (whooping cough), and poliomyelitis (polio). The vaccine helps the body to produce its own protection (antibodies) against these diseases.
None of the vaccine components can cause diphtheria, tetanus, pertussis, or polio.
Using Boostrix Polio during pregnancy will help protect your baby from pertussis in the first months of life, before they receive primary immunization.
Do not administer Boostrix Polio:
Warnings and precautions
Consult your doctor or pharmacist before you or your child receives Boostrix Polio:
Before or after any injection, dizziness may occur (especially in adolescents), so inform your doctor or nurse if you or your child has fainted after previous injections.
As with all vaccines, Boostrix Polio may not provide complete protection in all vaccinated patients.
Use of Boostrix Polio with other medications
Inform your doctor or pharmacist if you or your child is using, has used recently, or may need to use any other medication or if you have received recently any other vaccine.
Boostrix Polio can be administered at the same time as some vaccines. Use a different injection site for each type of vaccine, as the injection site will be different.
Boostrix Polio may not provide an adequate response if you or your child takes medications that reduce the effectiveness of your immune system against infections.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before receiving this vaccine.
The passage of Boostrix Polio into breast milk is unknown. Your doctor will inform you of the possible risks and benefits of administering Boostrix Polio during breastfeeding.
Driving and operating machinery
It is unlikely that Boostrix Polio will have any effect on your ability to drive vehicles and operate machines.
Boostrix Polio contains neomycin and polymyxin
This vaccine contains neomycin and polymyxin (antibiotics). Please inform your doctor if you or your child has had an allergic reaction to these components.
Boostrix Polio contains para-aminobenzoic acid, phenylalanine, sodium, and potassium
Boostrix Polio contains para-aminobenzoic acid. It may cause allergic reactions (possibly delayed) and, exceptionally, bronchospasm.
This vaccine contains 0.0298 micrograms of phenylalanine in each dose. Phenylalanine may be harmful in cases of phenylketonuria (PKU), a rare genetic disease in which phenylalanine accumulates because the body is unable to eliminate it correctly.
This vaccine contains less than 1 mmol of sodium (23 mg) per dose; it is essentially “sodium-free”.
This vaccine contains potassium, less than 1 mmol (39 mg) per dose; it is essentially “potassium-free”.
Like all medicines, Boostrix Polio can cause side effects, although not everyone will experience them.
As with all injectable vaccines, it may cause severe allergic reactions (anaphylactic and anaphylactoid reactions) in very rare occasions (up to a maximum of 1 in 10,000 doses of the vaccine). These can be recognized by:
These reactions may occur before leaving the doctor's consultation. However,if you notice any of these symptoms in yourself or your child, you must contact your doctor immediately.
Side effects that have occurred during clinical trials in children aged 4 to 8 years
Very common(may occur with more than 1 in 10 doses of the vaccine): pain, redness and inflammation at the injection site, feeling sleepy.
Common(may occur up to 1 in 10 doses of the vaccine): fever equal to or greater than 37.5°C (including fever greater than 39°C), bleeding, itching and hardening at the injection site, extensive swelling of the limb where the vaccine was applied, loss of appetite, irritability, headache.
Uncommon(may occur up to 1 in 100 doses of the vaccine): diarrhea, nausea, vomiting, stomach pain, inflammation of the lymph nodes in the neck, armpits or groin (lymphadenopathy), difficulty sleeping, apathy, dry throat, fatigue.
Coadministration with measles, mumps and rubella (MMR) vaccine or measles, mumps, rubella and varicella (MMRV) vaccine in children aged 3-6 years
In studies where Boostrix Polio was administered at the same time as the MMR or MMRV vaccines, skin eruptions and upper respiratory tract infections (including nasal discharge and sore throat) were frequently reported. Fever, irritability, fatigue, loss of appetite and gastrointestinal disturbances (including diarrhea and vomiting) were reported more frequently (very common) than in studies where Boostrix Polio was administered alone.
Side effects that have occurred during clinical trials in adults, adolescents and children aged 10 years and above:
Very common(may occur with more than 1 in 10 doses of the vaccine): pain, redness and inflammation at the injection site, fatigue, headache.
Common(may occur up to 1 in 10 doses of the vaccine): fever equal to or greater than 37.5°C, bruising, itching, hardening, warmth at the injection site, stomach pain, nausea, vomiting.
Uncommon(may occur up to 1 in 100 doses of the vaccine): fever greater than 39°C, extensive swelling of the limb where the vaccine was applied, chills, pain, dizziness, joint pain, muscle pain, itching, oral herpes, lymphadenopathy, loss of appetite, tingling or numbness in the hands or feet (paresthesia), drowsiness, asthma.
The following side effects occurred during routine use of Boostrix Polio and are not specific to any age group:collapse or loss of consciousness, swelling of the face, lips, mouth, tongue or throat that may cause difficulty swallowing or breathing (angioedema), seizures (with or without fever), hives (urticaria), unusual weakness (asthenia).
Additionally, the following side effects were reported during clinical trials with Boostrix (GlaxoSmithKline booster vaccine against diphtheria, tetanus and pertussis):
Side effects that have occurred in children aged 4 to 8 years
Uncommon(may occur up to 1 in 100 doses of the vaccine):attention disorders, discharge with itching of the eyes and eyelids with crust (conjunctivitis), dolor.
Side effects that have occurred in adults, adolescents and children aged 10 years and above
Very common(may occur with more than 1 in 10 doses of the vaccine):general malaise.
Common(may occur up to 1 in 10 doses of the vaccine):indurationor abscess at the injection site.
Uncommon(may occur up to 1 in 100 doses of the vaccine):upper respiratory tract infection, sore throat and difficulty swallowing (pharyngitis), fainting (syncope), cough, diarrhea, excessive sweating (hyperhidrosis), skin eruption, joint stiffness, muscle stiffness and joint stiffness, symptomssimilar to the flu, such as fever, sore throat, runny nose, cough and chills.
After administration of tetanus vaccines, in very rare occasions (up to a maximum of 1 in 10,000 doses of the vaccine) cases of temporary inflammation of the nerves have been reported, which cause pain, weakness and paralysis in the limbs and often reach the chest and face (Guillain-Barré syndrome).
Reporting of side effects
If you or your child experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use,www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this vaccine out of sight and reach of children.
Do not use this vaccine after the expiration date that appears on the packaging and on the pre-filled syringe label after CAD. The expiration date is the last day of the month indicated.
Store in a refrigerator (between 2°C and 8°C).
Do not freeze. Freezing destroys the vaccine.
Store in the original packaging to protect it from light.
Drugs should not be disposed of through drains or in the trash. Dispose of the containers and unused medications at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of unused containers and medications. By doing so, you will help protect the environment.
Diphtheria toxoid1no less than 2 International Units (UI) (2.5 Lf)
Tetanus toxoid1no less than 20 International Units (UI) (5 Lf)
Antigens ofBordetella pertussis
Pertussis toxoid18 micrograms
Filamentous hemagglutinin18 micrograms
Pertactin12.5 micrograms
Inactivated poliovirus
Type 1 (Mahoney strain)240 antigen units D
Type 2 (MEF-1 strain)28 antigen units D
Type 3 (Saukett strain)232 antigen units D
1adsorbed on hydrated aluminum hydroxide (Al(OH)3)0.3 milligrams Al3+
and aluminum phosphate (AlPO4)0.2 milligrams Al3+
2propagated in Vero cells
Aluminum hydroxide and aluminum phosphate are included in the vaccine as adjuvants.
Adjuvants are substances included in certain vaccines to accelerate, improve, and/or prolong the protective effect of the vaccine.
Appearance of the product and contents of the package
Injectable suspension in a pre-filled syringe.
Boostrix Polio is a white, slightly milky liquid presented in a pre-filled syringe (0.5 ml).
Boostrix Polio is available in pre-filled syringe of 1 dose with or without separate needles; package sizes of 1 and 10.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer responsible
Marketing authorization holder
GlaxoSmithKline, S.A.
P.T.M - C/ Severo Ochoa, 2
28760 Tres Cantos
Madrid
Tel: 900 202 700
Manufacturer responsible
GlaxoSmithKline Biologicals S.A.
Rue de l' Institut 89; 1330 Rixensart
Belgium
This medicinal product is authorized in the Member States of the European Economic Area with the following names:
Boostrix Polio:Belgium, Bulgaria, Czech Republic, Denmark, Germany, Greece, Spain, Iceland, Latvia, Lithuania, Luxembourg, Hungary, Netherlands, Norway, Austria, Poland, Portugal, Slovenia, Finland, Sweden
Boostrix Polio Lag:Slovak Republic
Boostrix Tetra:France
IPV-Boostrix:Ireland, Malta
Polio Boostrix:Italy
Boostrix-IPV:Romania
Last review date of this leaflet: April 2023
Other sources of information
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).
-------------------------------------------------------------------------------------------------------------------
This information is intended solely for healthcare professionals:
Before use, the vaccine should be left at room temperature and shaken well to obtain a white, turbid, and homogeneous suspension. Before administration, the vaccine should be visually examined to observe any foreign particles and/or variation in physical appearance. In case of observing any of these circumstances, do not administer the vaccine.
Instructions for the pre-filled syringe
Hold the syringe by the body, not by the plunger. Remove the syringe cap by turning it counterclockwise. | |
To insert the needle, connect the base to the luer-lock adapterand turn it a quarter of a turn in the direction of the clock until it feels locked. Do not remove the plunger from the syringe body. If this occurs, do not administer the vaccine. |
Disposal of residues:
The disposal of unused medicinal product and all materials that have been in contact with it, will be carried out in accordance with local regulations.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.